Cathleen Nientiedt

Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair–Associated Genes

Clemens Kratochwil, Frederik L. Giesel, Claus Peter Heußel et al. · Journal of Nuclear Medicine · 2019 · 81 citations

The BRCA2 mutation status shapes the immune phenotype of prostate cancer

Maximilian Jenzer, Peter Keß, Cathleen Nientiedt et al. · Cancer Immunology Immunotherapy · 2019 · 51 citations · Full text

Immunology, Immunoediting, Pathology +16

Mutations in BRCA2 and taxane resistance in prostate cancer

Cathleen Nientiedt, Martina Heller, Volker Endris et al. · Scientific Reports · 2017 · 42 citations · Full text

Tumor Biology, Urology, Brca1 Mutation +14

Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy

Xin Chen, Christof Bernemann, Yuri Tolkach et al. · Urologic Oncology Seminars and Original Investigations · 2017 · 41 citations

Prognostic Biomarkers, Urology, Medicine +6

Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer

Cathleen Nientiedt, Jan Budczies, Volker Endris et al. · Urologic Oncology Seminars and Original Investigations · 2021 · 35 citations · Full text